A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 29 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-07-28.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 10th largest by enrollment, is one of 5 that started in 2020, is one of 19 in phase 3, and was the 10th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 5 started in 2020.
This study's enrollment of 172 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 29th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2020, is one of 62 in phase 3, and was the 94th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study evaluate the long-term safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ ivacaftor (IVA) triple combination (TC) in participants with cystic fibrosis (CF) who are homozygous for F508del.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Part A: Participants received elexacaftor (ELX) 200 milligram (mg) once daily (qd)/tezacaftor (TEZ)100 mg qd/ivacaftor (IVA)150 mg every 12 hours (q12h) in the treatment period for 48 weeks. Part B: Participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period up to 86 weeks.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed-dose combination (FDC) tablet for oral administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Tablet for oral administration.
Also known as: VX-770, ivacaftor
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Week 52
Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Week 86
| Milestone | ELX/TEZ/IVA |
|---|---|
| Started | 172 |
| Completed | 159 |
| Not completed | 13 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal of consent (not due to ae) | 4 |
| Withdrew: Commercial drug is available for participant | 2 |
| Withdrew: Other | 5 |
| Milestone | ELX/TEZ/IVA |
|---|---|
| Started | 50 |
| Completed | 0 |
| Not completed | 50 |
| Withdrew: Commercial drug is available for participant | 46 |
| Withdrew: Other | 4 |
| Participants | Part A: ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 160 |
| Participants with SAEs | 26 |
| Participants | Part B: ELX/TEZ/IVA |
|---|---|
| Participants with TEAEs | 50 |
| Participants with SAEs | 8 |
Collected over Day 1 up to Week 52 for Part A, Day 1 up to Week 86 for Part B. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: ELX/TEZ/IVA | 0/172 (0%) | 26/172 (15.1%) | 127/172 (73.8%) |
| Part B: ELX/TEZ/IVA | 0/50 (0%) | 8/50 (16%) | 47/50 (94%) |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 8/172 | 5/50 |
| CholecystitisHepatobiliary disorders | 0/172 | 1/50 |
| Limb traumatic amputationInjury, poisoning and procedural complications | 0/172 | 1/50 |
| Forced expiratory volume decreasedInvestigations | 0/172 | 1/50 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/172 | 1/50 |
| Alanine aminotransferase increasedInvestigations | 2/172 | 0/50 |
| Aspartate aminotransferase increasedInvestigations | 2/172 | 0/50 |
| Atrial fibrillationCardiac disorders | 1/172 | 0/50 |
| Myocardial infarctionCardiac disorders | 1/172 | 0/50 |
| Sinus arrestCardiac disorders | 1/172 | 0/50 |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 17/172 | 21/50 |
| COVID-19Infections and infestations | 2/172 | 17/50 |
| NasopharyngitisInfections and infestations | 28/172 | 16/50 |
| HeadacheNervous system disorders | 42/172 | 10/50 |
| Upper respiratory tract infectionInfections and infestations | 10/172 | 11/50 |
| PyrexiaGeneral disorders | 7/172 | 8/50 |
| Immunisation reactionImmune system disorders | 0/172 | 7/50 |
| Vaccination complicationInjury, poisoning and procedural complications | 24/172 | 0/50 |
| CoughRespiratory, thoracic and mediastinal disorders | 23/172 | 5/50 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 4/172 | 6/50 |
Baseline data is based on the parent study baseline, which is defined as the most recent non-missing measurements collected before the first dose of the study drug in the treatment period of parent studies. Baseline data is presented for participants who received at least 1 dose of study drug in this study.
| Age, Continuous(years) | ELX/TEZ/IVA |
|---|---|
| Part A | 27.9 ± 11.4 |
| Part B | 25.6 ± 12.0 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A — Female | 87 |
| Part A — Male | 85 |
| Part B — Female | 26 |
| Part B — Male | 24 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A — Hispanic or Latino | 3 |
| Part A — Not Hispanic or Latino | 167 |
| Part A — Not collected per local regulations | 2 |
| Part B — Hispanic or Latino | 1 |
| Part B — Not Hispanic or Latino | 49 |
| Part B — Not collected per local regulations | 0 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A — White | 169 |
| Part A — Black or African American | 0 |
| Part A — Asian | 2 |
| Part A — American Indian or Alaska Native | 0 |
| Part A — Native Hawaiian or Other Pacific Islander | 0 |
| Part A — White, Asian | 1 |
| Part A — Not collected per local regulations | 0 |
| Part B — White | 50 |
| Part B — Black or African American | 0 |
| Part B — Asian | 0 |
| Part B — American Indian or Alaska Native | 0 |
| Part B — Native Hawaiian or Other Pacific Islander | 0 |
| Part B — White, Asian | 0 |
| Part B — Not collected per local regulations | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing.
Ran from May 2020 to primary completion in Dec 2022, 31 months.
Results were first posted in Jul 2023, 7 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 31 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →